Jiangsu Hengrui Medicine has established a new subsidiary in Zhejiang, named Zhejiang Hengrui Pharmaceutical Co., Ltd. The new company has a registered capital of 50 million RMB and will engage in activities such as medical research and development, pharmaceutical wholesale, retail, and contract manufacturing. Jiangsu Hengrui Medicine is the sole shareholder of this new entity. AI
RANK_REASON This is a new company formation and subsidiary establishment, which falls under the 'tool' category as it represents a business operational move rather than a core AI release, research, or significant industry event.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →